Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | PREP | P48147 | 1/20 | 0.47 |
| ▸ | FAP | Q12884 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | MTTP | P55157 | 2/20 | 0.44 |
| ▸ | TACR1 | P25103 | 1/20 | 0.44 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5525818 | 0.85 | ALDH1A1 (0.47) | ALDH1A1HPGDTACR1KCNA3KMT2A | |
| SCHEMBL718729 | 0.85 | ACE (0.49) | ALDH1A1KMT2A | |
| SCHEMBL714622 | 0.84 | NPC1 (0.46) | ALDH1A1HPGDPREPKCNA3KMT2A | |
| SCHEMBL14434719 | 0.82 | ALDH1A1 (0.43) | ALDH1A1HPGDKCNA3KMT2A | |
| SCHEMBL12949920 | 0.79 | KMT2A (0.53) | ALDH1A1HPGDPREPFAPKMT2A | |
| SCHEMBL12949802 | 0.78 | PREP (0.43) | PREPFAP | |
| SCHEMBL8288957 | 0.76 | CCR1 (0.44) | PREP | |
| SCHEMBL12949799 | 0.76 | PREP (0.44) | PREPFAPKMT2A | |
| SCHEMBL14181582 | 0.75 | STAT6 (0.42) | — | |
| SCHEMBL16708322 | 0.74 | F2RL3 (0.49) | PREPFAPKCNH2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183280-B2 | FAP inhibitors | VANTIA LIMITED (GB) | 2012-05-22 | — | — | US | disclosed |
| US-20100081701-A1 | FAP inhibitors | VANTIA LIMITED (GB) | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081701-A1 | FAP inhibitors | FAP, APC, SERPINB1 | ALDH1A1 379/4885HPGD 1039/4885PREP 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.